GCP
CATX icon

GSA Capital Partners’s Perspective Therapeutics CATX Stock Holding History

GSA Capital Partners’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$156K Sell
37,317
-48,895
-57% -$207K 0.01% 1508
2025
Q4 		$237K Buy
+86,212
New +$246K 0.02% 1304
2015
Q3 		– Sell
-4,810
Closed -$71K – 1763
2015
Q2 		$71K Buy
4,810
+3,610
+301% +$58.5K ﹤0.01% 1885
2015
Q1 		$19K Buy
+1,200
New +$17.8K ﹤0.01% 2075

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's CATX Position: Q1 2026 in Review

GSA Capital Partners reduced its Perspective Therapeutics (CATX) stake by 57% in Q1 2026, selling an estimated $207K and leaving 37,317 shares worth $156K. The position accounts for 0.01% of the portfolio, ranked #1508.

GSA Capital Partners first reported a position in CATX in Q1 2015 and has held it in 4 quarters since. The position peaked at $237K in Q4 2025. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • GSA Capital Partners held 37,317 shares of Perspective Therapeutics worth $156K as of Q1 2026.
  • GSA Capital Partners sold 48,895 Perspective Therapeutics shares in Q1 2026, an estimated $207K.
  • Perspective Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1508 holding.
  • GSA Capital Partners first reported a position in Perspective Therapeutics in Q1 2015 and has held it in 4 quarters since.
  • GSA Capital Partners's Perspective Therapeutics position peaked at $237K in Q4 2025.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.